FDA Extends Decision Date for AstraZeneca's Camizestrant in HR-positive Breast Cancer
The FDA has extended the PDUFA date for camizestrant to allow for additional data review related to its NDA.
Regulatory Event
Prescription Drug User Fee Act action dates and FDA review timelines for new drug and biologics applications.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.